The present technology is directed generally to devices, systems, and methods for the treatment of vascular defects.
Aneurysms are blood-filled dilations of a blood vessel generally caused by disease or weakening of the blood vessel wall. The wall of the aneurysm may progressively thin, which increases the risk of rupture causing hemorrhagic stroke or even sudden death. There are about 30,000 to 40,000 cases of aneurysmal rupture per year in the United States, accounting for about 5% of all strokes. The prognosis after aneurysmal rupture is poor; the 30-day mortality rate is approximately 45% and a positive functional outcome is achieved in only 40-50% of survivors. Traditional approaches to preventing aneurysmal rupture often include packing the aneurysm with metal coils to reduce the inflow of blood to the aneurysm and prevent further enlargement and rupture. Such coils are often referred to as “embolic coils” or “microcoils,” and can be categorized into the following three groups based on their structural properties: framing coils, filling coils, and finishing coils. Framing coils are inserted first into the aneurysm and form the base structure into which the later-delivered filling coils are packed. As such, framing coils are stiffer than filling and finishing coils to provide structural stability and generally have a complex or three-dimensional shape for approximating the periphery of the aneurysm. Filling coils, in contrast, are softer than framing coils, and multiple filling coils are packed within the framework of the framing coil(s) to achieve a high packing density. Finishing coils are delivered last to fill any remaining gaps left between filling coils.
Embolic coils, however, have several drawbacks. First, embolic coils generally only achieve a 20-40% packing density (i.e., ratio of the volume of the coils inserted into the aneurysm sac and the volume of the aneurysm sac). As a result, blood continues to flow into the aneurysm (also known as recanalization) in about 30% of coil cases, which can cause further swelling of the aneurysm over time. In addition, because the coils must be very small to fit within a microcatheter for delivery through the tiny cranial vessels, numerous coils are often required to adequately fill the aneurysm. These numerous coils must be delivered one-by-one, thereby increasing procedure time and complexity. Yet another drawback is that embolic coils cannot accommodate the wide range of aneurysm shapes and sizes. Embolic coils, for example, are difficult to stabilize within wide-necked aneurysms, which can result in migration of one or more coils across the neck such that a portion of the migrated coil(s) protrudes into the parent blood vessel. The protruding portion of the migrated coil(s) can be a nidus for thromboembolism, which can be fatal if left unaddressed. To address this shortcoming, many existing treatments include positioning an intracranial stent across the neck of the aneurysm to prevent all or part of a coil from migrating across the neck. However, intracranial stents can also be a nidus for thromboembolism, and further increase procedure time and cost. Thus, there is a need for improved devices, systems, and methods for treating aneurysms.
The present technology is directed generally to devices, systems, and methods for the treatment of vascular defects, and in particular, to vascular occlusion devices for treating hemorrhagic stroke. In some embodiments, the present technology includes an expandable occlusion device comprising a mesh structure having a low-profile state for intravascular delivery to an aneurysm and an expanded state in which the mesh is configured to be positioned within the interior cavity of the aneurysm. As used herein, “mesh” or “mesh structure” may refer to a stent, a braid, a lattice, a weave, a laser-cut sheet, and/or any other suitable porous structures. In some embodiments, the occlusion device includes a mesh structure having two or more mesh portions that have different shapes and/or configurations. The mesh portions complement one another when positioned together within the aneurysm to stabilize and/or anchor the mesh within the aneurysm, fill space within the aneurysm, and/or seal the neck of the aneurysm to prevent or reduce blood flow therethrough.
The subject technology is illustrated, for example, according to various aspects described below. Various examples of aspects of the subject technology are described as numbered clauses (1, 2, 3, etc.) for convenience. These are provided as examples and do not limit the subject technology. It is noted that any of the dependent clauses may be combined in any combination, and placed into a respective independent clause, e.g., clause [1, 17, and 31]. The other clauses can be presented in a similar manner.
Clause 1. An occlusive device for treating an aneurysm, wherein a neck of the aneurysm opens to a blood vessel, the device comprising:
Clause 2. The device of Clause 1, wherein the first and second elongated meshes are self-expanding.
Clause 3. The device of Clause 1 or Clause 2, wherein the first and second bands together bound a generally spherical shape, and wherein the first and second bands conform to an interior geometry of the aneurysm when the device is positioned within the aneurysm.
Clause 4. The device of any one of Clauses 1-3, wherein the device is configured to be positioned in the aneurysm in an expanded state such that the first or second overlap region is positioned at the neck of the aneurysm, thereby substantially covering the neck and reducing blood flow through the neck from a parent vessel.
Clause 5. The device of any one of Clauses 1-4, wherein the first axis is generally perpendicular to the second axis.
Clause 6. The device of any one of Clauses 1-5, wherein each of the first and second bands have a generally constant width along their respective circumferential lengths.
Clause 7. The device of any one of Clauses 1-6, further comprising a third elongated mesh having a low-profile state for intravascular delivery to the aneurysm and an expanded state in which the third elongated mesh is curved about a third axis different than the first axis and the second axis to form a third band.
Clause 8. The device of any one of Clauses 1-7, wherein at least one of the first elongated mesh and the second elongated mesh is a braid.
Clause 9. The device of any one of Clauses 1-8, wherein at least one of the first elongated mesh and the second elongated mesh is a flattened tubular braid.
Clause 10. The device of any one of Clauses 1-9, wherein the device includes a flexible joint between a distal end of the first elongated mesh and a proximal end of the second elongated mesh.
Clause 11. The device of Clause 10, wherein the first elongated mesh and the second elongated mesh are formed of a single, continuous elongated mesh, and wherein the joint is a narrowed region of the mesh configured to direct a proximal portion of the second elongated mesh away from the first band when the device is in an expanded state.
Clause 12. The device of Clause 10, wherein the first elongated mesh and second elongated mesh are discrete, separate meshes, and wherein the joint is a coupler.
Clause 13. The device of any one of Clauses 1-12, wherein the first and second elongated meshes have at least two layers such that the first and second overlap regions of the device include at least four mesh layers.
Clause 14. The device of any one of Clauses 1-13, wherein a proximal end of the first elongated mesh is configured to be detachably coupled to an elongated delivery member.
Clause 15. The device of any one of Clauses 1-14, wherein a distal end of the second elongated mesh is coupled to an atraumatic lead-in member that extends distally from the second elongated mesh.
Clause 16. The device of any one of Clauses 1-15, wherein the device includes a plurality of openings between the first and second elongated meshes.
Clause 17. The device of any one of Clauses 1-16, wherein:
Clause 18. The device of any one of Clauses 1-16, wherein:
Clause 19. The device of any one of Clauses 1-18, wherein, in the expanded state, the first band is an open band such that when the first band is viewed in cross section, it does not form a closed shape.
Clause 20. The device of any one of Clauses 1-19, wherein, in the expanded state, the second band is an open band such that when the second band is viewed in cross section, it does not form a closed shape.
Clause 21. The device of any one of Clauses 1-18 and 20, wherein, in the expanded state, the first band is a closed band such that when the first band is viewed in cross section, it forms a closed shape.
Clause 22. The device of any one of Clauses 1-19 and 21, wherein, in the expanded state, the second band is a closed band such that when the second band is viewed in cross section, it forms a closed shape.
Clause 23. The device of any one of Clauses 1-22, wherein the first and second bands together bound a predetermined, three-dimensional shape.
Clause 24. An occlusive device for treating an aneurysm, wherein a neck of the aneurysm opens to a blood vessel, the device comprising:
Clause 25. The device of Clause 24, wherein the first, second, and third elongated mesh strips are self-expanding.
Clause 26. The device of any one of Clause 24 or Clause 25, wherein the first, second, and third bands together bound a generally spherical shape, and wherein the first, second, and third bands conform to an interior geometry of the aneurysm when the device is positioned within the aneurysm.
Clause 27. The device of any one of Clauses 24-26, wherein the device includes:
Clause 28. The device of Clause 27, wherein the device is configured to be positioned in the aneurysm in an expanded state such that at least one of the first-sixth overlap regions are positioned at the neck of the aneurysm, thereby substantially covering the neck and reducing blood flow from a parent vessel through the neck.
Clause 29. The device of any one of Clauses 24-28, wherein at least one of the first, second, and third elongated mesh strips is a braid.
Clause 30. The device of any one of Clauses 24-29, wherein at least one of the first, second, and third elongated mesh strips is a flattened tubular braid.
Clause 31. The device of any one of Clauses 24-30, wherein a distal end of the first elongated mesh strip is coupled to a proximal end of the second elongated mesh strip at a first joint, and a distal end of the second elongated mesh strip is coupled to a proximal end of the third elongated mesh strip at a second joint.
Clause 32. The device of any one of Clauses 24-31, wherein the third elongated mesh is configured to be released from a delivery catheter before the second elongated mesh, and the second elongated mesh is configured to be released from a delivery catheter before the first elongated mesh.
Clause 33. The device of any one of Clauses 24-32, wherein a proximal end of the first elongated mesh strip is configured to be detachably coupled to an elongated delivery member.
Clause 34. The device of any one of Clauses 24-33, wherein a distal end of the third elongated mesh strip is coupled to an atraumatic lead-in member that extends distally from the third elongated mesh.
Clause 35. The device of any one of Clauses 24-34, wherein, when the device is in an expanded, unconstrained state, the third band is radially inward of the second band, and the second band is radially inward of the first band.
Clause 36. The device of any one of Clauses 24-35, wherein the first, second, and third elongated mesh strips are formed of a single, continuous elongated mesh.
Clause 37. The device of any one of Clauses 24-35, wherein the first, second, and third elongated mesh strips are discrete, separate meshes.
Clause 38. The device of any one of Clauses 24-37, wherein:
Clause 39. The device of any one of Clauses 24-37, wherein:
Clause 40. The device of any one of Clauses 24-39, wherein, in the expanded state, the first band is an open band such that when the first band is viewed in cross section, it does not form a closed shape.
Clause 41. The device of any one of Clauses 24-40, wherein, in the expanded state, the second band is an open band such that when the second band is viewed in cross section, it does not form a closed shape.
Clause 42. The device of any one of Clauses 24-41, wherein, in the expanded state, the third band is an open band such that when the third band is viewed in cross section, it does not form a closed shape.
Clause 43. The device of any one of Clauses 24-39, 41, or 42, wherein, in the expanded state, the first band is a closed band such that when the first band is viewed in cross section, it forms a closed shape.
Clause 44. The device of any one of Clauses 24-40, 42, or 43, wherein, in the expanded state, the second band is a closed band such that when the second band is viewed in cross section, it forms a closed shape.
Clause 45. The device of any one of Clauses 24-41, 43, or 44, wherein, in the expanded state, the third band is a closed band such that when the third band is viewed in cross section, it forms a closed shape.
Clause 46. The device of any one of Clauses 24-45, wherein the first, second, and third bands together bound a predetermined, three-dimensional shape.
Clause 47. A method for treating an aneurysm with an occlusive device including a first elongated mesh and a second elongated mesh, wherein a neck of the aneurysm opens to a blood vessel, the method comprising:
Clause 48. The method of Clause 47, wherein the first elongated mesh is pushed distally from the delivery catheter before the second elongated mesh is pushed distally from the delivery catheter.
Clause 49. The method of Clause 47 or Clause 48, wherein:
Clause 50. The method of Clause 49, wherein the first axis is perpendicular to the second axis.
Clause 51. The method of any one of Clauses 47-50, wherein the first and second elongated meshes are formed of a single, continuous elongated mesh.
Clause 52. The method of any one of Clauses 47-50, wherein the first and second elongated meshes are discrete, separate meshes.
Clause 53. The method of any one of Clauses 47-52, further comprising pushing a third elongated mesh distally from the delivery catheter into the interior region of the aneurysm, wherein pushing the third elongated mesh distally includes curving the third elongated mesh back on itself to form a third band that expands against and conforms to the inner surface of the aneurysm wall.
Clause 54. The method of Clause 53, wherein the third band is an open band.
Clause 55. The method of Clause 53, wherein the third band is a closed band.
Clause 56. The method of any one of Clauses 53-55, wherein:
Clause 57. The method of Clause 56, further comprising positioning the device within the aneurysm such that one or more of the first-sixth overlap regions are positioned at the neck of the aneurysm.
Clause 58. The method of any one of Clauses 53-57, wherein:
Clause 59. The method of Clause 58, wherein the first, second, and third axes are perpendicular to one another.
Clause 60. The method of any one of Clauses 47-59, wherein the first band is an open band.
Clause 61. The method of any one of Clauses 47-59, wherein the first band is a closed band.
Clause 62. The method of any one of Clauses 47-61, wherein the second band is an open band.
Clause 63. The method of any one of Clauses 47-61, wherein the second band is a closed band.
Clause 64. A method for treating an aneurysm comprising positioning any one of the occlusive devices of Clauses 1-46 within an aneurysm.
Clause 64. A method for treating an aneurysm comprising positioning two or more of the occlusive devices of Clauses 1-46 within an aneurysm, in succession.
The detailed description set forth below is intended as a description of various configurations of the subject technology and is not intended to represent the only configurations in which the subject technology may be practiced. The appended drawings are incorporated herein and constitute a part of the detailed description. The detailed description includes specific details for the purpose of providing a thorough understanding of the subject technology. However, the subject technology may be practiced without these specific details.
The mesh ribbon 107 can be formed of a tubular mesh that has been flattened along its longitudinal axis such that opposing portions of the sidewall are pressed against one another and/or into close proximity with one another. In some embodiments, the mesh ribbon 107 is formed of a flattened tubular braid. The braid may be formed of a plurality of wires, at least some of which (e.g., 25% of the wires, 50% of the wires, 80% of the wires, 100% of the wires, etc.) are made of one or more shape memory and/or superelastic materials (e.g., Nitinol). In some embodiments, at least some of the plurality of wires may be drawn-filled tubes (“DFT”) having a have a radiopaque core (e.g., platinum) surrounded by a shape memory alloy and/or superelastic alloy (e.g., Nitinol). In these and other embodiments, at least a portion of the wires can be made of other suitable materials.
In some embodiments, the mesh ribbon 107 includes a plurality of band portions 142, 144, 146 positioned along its longitudinal axis L, and one or more bend portions 112 individually positioned between adjacent band portions 142, 144, 146 along the longitudinal axis L. The first, second, and third band portions 142, 144, 146 may be configured to form the first, second, and third bands 122, 124, 126, respectively, when the mesh structure 102 is in the expanded state. For example, as shown in
The occlusion device 100 is configured to be positioned in a compressed or low-profile state within a delivery catheter (e.g., a microcatheter) so that the distal end 102b of the mesh structure 102 is closest to the distal opening of the catheter and thus will be released from the delivery catheter first. Accordingly, the third band 126 deploys first from the delivery catheter, followed by the second band 124 and the first band 122. As a result, the second band 124 expands within an interior region defined by the already-expanded third band 126, and the first band 122 expands within an interior region defined by the already-expanded second band 124. Thus, when the mesh structure 102 is in an expanded configuration positioned within the aneurysm, the second band 124 is positioned radially inward of the third band 126, and the first band 122 is positioned radially inward of the second band 124. Even if one of the bands 122, 124, 126 is positioned radially inwardly of another of the bands 122, 124, 126 in the expanded configuration, when the mesh structure 102 is expanded within an aneurysm, any radially inward band may still contact and conform to the inner surface of the aneurysm along its non-overlapping regions, especially if the diameter of the mesh structure 102 in the expanded, relaxed state is greater than that of the aneurysm. In some embodiments, when the mesh structure 102 is in an expanded state, an outer surface of the second band 124 contacts an inner surface of the third band 126 at the corresponding overlapping regions, and an outer surface of the first band 122 contacts an inner surface of the second band 124 at the corresponding overlapping regions.
Because the bands 122, 124, 126 are oriented along different planes, the bands 122, 124, 126 overlap one another along their respective circumferences, thereby forming a plurality of overlapping regions in which the porosity of the mesh structure 102 is less than it is at the non-overlapping regions of the mesh structure 102. For example, as shown in
In some embodiments, for example as shown in
Each of the bands 122, 124, 126 may be a closed band (e.g., circumscribes a closed shape) (shown schematically in
The bands 122, 124, 126/band portions 142, 144, 146 can have the same or different widths w (i.e., distance between the side edges 110a, 110b) as the other bands/band portions. As shown in
As shown in
Referring to
In some embodiments the occlusion device 100 may optionally include a soft, curved lead-in member 108 coupled to the distal end portion 102b of the mesh structure 102 via the distal connector 106. The lead-in member 108 may have a curved shape in a deployed configuration. For example, the lead-in member 108 initially extends distally with respect to the mesh structure 102 (e.g., from the distal connector 106) then curves proximally. Because the lead-in member 108 is the first portion of the occlusion device 100 that exits the delivery catheter and contacts the aneurysm wall, the soft material and/or curved shape of the lead-in member 108 reduces or eliminates stress on the aneurysm wall when delivering the occlusion device 100 to the aneurysm sac. In some embodiments the lead-in member 108 can be generally straight and/or have other atraumatic yet sufficiently resilient configurations. In some embodiments, the lead-in member 108 is a curled mesh (e.g., a braid) that is coupled to the distal connector 106. The curled mesh can be integral with the mesh that forms the mesh structure 102, or the curled mesh can be a separate mesh. In some embodiments, the lead-in member 108 is a separate, coiled tube (e.g., a radiopaque coil) that is coupled to the distal connector 106. In some embodiments, the lead-in member 108 can be formed integrally or monolithically with the occlusion device 100. In yet other embodiments, the occlusion device 100 does not include a lead-in member 108 and the distal portion of the occlusion device 100 is comprised solely of the distal connector 106 and/or distal end portion 102b of the mesh structure 102.
In some embodiments, the stiffness of the mesh structure 102 and/or occlusion device 100 is generally constant along its longitudinal axis L. In some embodiments, the stiffness of the mesh structure 102 and/or occlusion device 100 varies along its longitudinal axis L. For example, the stiffness of one or more portions of the mesh ribbon 107 and/or mesh structure 102 can be different than other portions of the mesh ribbon 107 and/or mesh structure 102 by varying one or more parameters such as the materials, porosity, thickness, braid count (if applicable), and braid pitch (if applicable) in the individual portions. For example, for the mesh ribbon 107 shown in
To enhance visibility of the occlusion device 100 and/or mesh structure 102 during delivery to the aneurysm and/or subsequent to implantation within the aneurysm, the occlusion device 100 may optionally include a flexible member (not shown), such as a radiopaque element (e.g., a platinum coil), that extends along and/or within at least a portion of the length of the mesh structure 102. The proximal and distal ends of the flexible member are coupled to the proximal and distal end portions 102a, 102b, respectively, of the mesh structure 102 and/or the proximal and distal connectors 104, 106, respectively (e.g., directly or via a suture). In other embodiments, only one end of the flexible member is connected to one of the proximal connector 104 or the distal connector 106.
2.0 Methods of Use
In use, the occlusion device 100 is intravascularly delivered to a location within a blood vessel lumen L adjacent a target aneurysm A in a low-profile configuration (not shown) within a delivery catheter 10. The distal portion of the delivery catheter 10 is then advanced through the neck N of the aneurysm A to an interior region of the aneurysm A. As shown in
3.0 Additional Embodiments
The globular first portion 404 can have a proximal connector 405 at its proximal end and a distal connector 412 at its distal end. The proximal connector 405 is configured to detachably couple the occlusion device 400 to a delivery device (such as delivery member 110). As such, the helical second portion 402 is configured to be delivered first to the aneurysm, followed by the first portion 404. The distal connector 412 may include a loop 416 extending therefrom and configured to engage and/or interlock with a loop 414 extending from a proximal connector 410 at a proximal end of the second portion 402. The interlocking loops 414, 416 allow the second portion 402 to bend and rotate (to some extent) relative to the first portion 404 (and vice versa), thus enabling the device 400 to adapt to the shape and size of the aneurysm.
The helical second portion 402 can be formed of a mesh ribbon 407 wrapped about an axis a plurality of times to form a plurality of mesh turns 403 (only two labeled for ease of illustration) in the expanded configuration. The mesh turns 403 may overlap one another along their edges. The mesh ribbon 407 can be formed of a tubular mesh (e.g., a braided tube) that has been flattened along its longitudinal axis such that opposing portions of the sidewall are pressed against one another and/or into close proximity with one another. In some embodiments, the mesh ribbon 407 is formed of a flattened tubular braid. The braid may be formed of a plurality of wires, at least some of which (e.g., 25% of the wires, 50% of the wires, 80% of the wires, 100% of the wires, etc.) are made of one or more shape memory and/or superelastic materials (e.g., Nitinol). In some embodiments, at least some of the plurality of wires may be drawn-filled tubes (“DFT”) having a have a radiopaque core (e.g., platinum) surrounded by a shape memory alloy and/or superelastic alloy (e.g., Nitinol). In these and other embodiments, at least a portion of the wires can be made of other suitable materials.
The globular first portion 704 can have a proximal connector 405 at its proximal end and a distal connector 412 at its distal end. The proximal connector 405 is configured to detachably couple the occlusion device 700 to a delivery device (such as delivery member 110). The distal connector 412 may include a loop 416 extending therefrom and configured to engage and/or interlock with a loop 414 extending from a proximal connector 410 at a proximal end of the second portion 702. The interlocking loops 414, 416 allow the second portion 702 to bend and rotate (to some extent) relative to the first portion 404 (and vice versa), thus enabling the device 700 to adapt to the aneurysm cavity.
The second portion 702 can include a plurality of rectangular regions 703 separated by flexible, narrowed bend regions 709. The second portion 702 may be formed of a mesh ribbon 707. The mesh ribbon 707 can be formed of a tubular mesh (e.g., a braided tube) that has been flattened along its longitudinal axis such that opposing portions of the sidewall are pressed against one another and/or into close proximity with one another. In some embodiments, the mesh ribbon 707 is formed of a flattened tubular braid. The braid may be formed of a plurality of wires, at least some of which (e.g., 25% of the wires, 50% of the wires, 80% of the wires, 100% of the wires, etc.) are made of one or more shape memory and/or superelastic materials (e.g., Nitinol). In some embodiments, at least some of the plurality of wires may be drawn-filled tubes (“DFT”) having a have a radiopaque core (e.g., platinum) surrounded by a shape memory alloy and/or superelastic alloy (e.g., Nitinol). In these and other embodiments, at least a portion of the wires can be made of other suitable materials.
Although many of the embodiments are described above with respect to devices, systems, and methods for treating a cerebral aneurysm, other applications and other embodiments in addition to those described herein are within the scope of the technology. For example, the occlusion devices, systems, and methods of the present technology can be used to treat any vascular defect and/or fill or partially fill any body cavity or lumen or walls thereof. Additionally, several other embodiments of the technology can have different states, components, or procedures than those described herein. It will be appreciated that specific elements, substructures, advantages, uses, and/or other features of the embodiments described can be suitably interchanged, substituted or otherwise configured with one another in accordance with additional embodiments of the present technology. A person of ordinary skill in the art, therefore, will accordingly understand that the technology can have other embodiments with additional elements, or the technology can have other embodiments without several of the features shown and described above.
This application is a continuation of U.S. patent application Ser. No. 15/683,627 filed Aug. 22, 2017, which is incorporated herein by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
5250071 | Palermo | Oct 1993 | A |
5354295 | Guglielmi et al. | Oct 1994 | A |
5645558 | Horton | Jul 1997 | A |
5669931 | Kupiecki et al. | Sep 1997 | A |
5725552 | Kotula et al. | Mar 1998 | A |
5733294 | Forber et al. | Mar 1998 | A |
5741333 | Frid | Apr 1998 | A |
5749891 | Ken et al. | May 1998 | A |
5749919 | Blanc | May 1998 | A |
5814062 | Sepetka et al. | Sep 1998 | A |
5911731 | Pham et al. | Jun 1999 | A |
5916235 | Guglielmi | Jun 1999 | A |
5925060 | Forber | Jul 1999 | A |
5928260 | Chin et al. | Jul 1999 | A |
5935148 | Villar et al. | Aug 1999 | A |
5944738 | Amplatz et al. | Aug 1999 | A |
5951599 | McCrory | Sep 1999 | A |
5964797 | Ho | Oct 1999 | A |
5976169 | Imran | Nov 1999 | A |
5980554 | Lenker et al. | Nov 1999 | A |
6022374 | Imran | Feb 2000 | A |
6033423 | Ken et al. | Mar 2000 | A |
6036720 | Abrams et al. | Mar 2000 | A |
6059812 | Clerc et al. | May 2000 | A |
6063070 | Eder | May 2000 | A |
6063104 | Villar et al. | May 2000 | A |
6086577 | Ken et al. | Jul 2000 | A |
6090125 | Horton | Jul 2000 | A |
6093199 | Brown et al. | Jul 2000 | A |
6096021 | Helm et al. | Aug 2000 | A |
6123715 | Amplatz | Sep 2000 | A |
6139564 | Teoh | Oct 2000 | A |
6152144 | Lesh et al. | Nov 2000 | A |
6159531 | Dang et al. | Dec 2000 | A |
6168615 | Ken et al. | Jan 2001 | B1 |
6168622 | Mazzocchi | Jan 2001 | B1 |
6309367 | Boock | Oct 2001 | B1 |
6344048 | Chin et al. | Feb 2002 | B1 |
6346117 | Greenhalgh | Feb 2002 | B1 |
6350270 | Roue | Feb 2002 | B1 |
6368339 | Amplatz | Apr 2002 | B1 |
6371980 | Rudakov et al. | Apr 2002 | B1 |
6375668 | Gifford et al. | Apr 2002 | B1 |
6383174 | Eder | May 2002 | B1 |
6391037 | Greenhalgh | May 2002 | B1 |
6428558 | Jones et al. | Aug 2002 | B1 |
6447531 | Amplatz | Sep 2002 | B1 |
6451050 | Rudakov et al. | Sep 2002 | B1 |
6454780 | Wallace | Sep 2002 | B1 |
6494884 | Gifford et al. | Dec 2002 | B2 |
6506204 | Mazzocchi | Jan 2003 | B2 |
6511468 | Cragg et al. | Jan 2003 | B1 |
6547804 | Porter et al. | Apr 2003 | B2 |
6551303 | Van et al. | Apr 2003 | B1 |
6579303 | Amplatz | Jun 2003 | B2 |
6585748 | Jeffree | Jul 2003 | B1 |
6589256 | Forber | Jul 2003 | B2 |
6589265 | Palmer et al. | Jul 2003 | B1 |
6599308 | Amplatz | Jul 2003 | B2 |
6602261 | Greene et al. | Aug 2003 | B2 |
6605101 | Schaefer et al. | Aug 2003 | B1 |
6605102 | Mazzocchi et al. | Aug 2003 | B1 |
6605111 | Bose et al. | Aug 2003 | B2 |
6613074 | Mitelberg et al. | Sep 2003 | B1 |
6626939 | Burnside et al. | Sep 2003 | B1 |
6635068 | Dubrul et al. | Oct 2003 | B1 |
6652556 | Vantassel et al. | Nov 2003 | B1 |
6666882 | Bose et al. | Dec 2003 | B1 |
6669721 | Bose et al. | Dec 2003 | B1 |
6682546 | Amplatz | Jan 2004 | B2 |
6689486 | Ho et al. | Feb 2004 | B2 |
6730108 | Van et al. | May 2004 | B2 |
6746468 | Sepetka et al. | Jun 2004 | B1 |
6746890 | Gupta et al. | Jun 2004 | B2 |
6780196 | Chin et al. | Aug 2004 | B2 |
6802851 | Jones et al. | Oct 2004 | B2 |
6811560 | Jones et al. | Nov 2004 | B2 |
6855153 | Saadat | Feb 2005 | B2 |
6855154 | Abdel-Gawwad | Feb 2005 | B2 |
6878384 | Cruise et al. | Apr 2005 | B2 |
6905503 | Gifford et al. | Jun 2005 | B2 |
6936055 | Ken et al. | Aug 2005 | B1 |
6991617 | Hektner et al. | Jan 2006 | B2 |
6994092 | Van et al. | Feb 2006 | B2 |
6994717 | Konya et al. | Feb 2006 | B2 |
7011671 | Welch | Mar 2006 | B2 |
7029487 | Greene et al. | Apr 2006 | B2 |
7083632 | Avellanet et al. | Aug 2006 | B2 |
7128073 | Van et al. | Oct 2006 | B1 |
7128736 | Abrams et al. | Oct 2006 | B1 |
7169177 | Obara | Jan 2007 | B2 |
7195636 | Avellanet et al. | Mar 2007 | B2 |
7229461 | Chin et al. | Jun 2007 | B2 |
7232461 | Ramer | Jun 2007 | B2 |
7326225 | Ferrera et al. | Feb 2008 | B2 |
7331980 | Dubrul et al. | Feb 2008 | B2 |
7419503 | Pulnev et al. | Sep 2008 | B2 |
7597704 | Frazier et al. | Oct 2009 | B2 |
7601160 | Richter | Oct 2009 | B2 |
7708754 | Balgobin et al. | May 2010 | B2 |
7879064 | Monstadt et al. | Feb 2011 | B2 |
RE42625 | Guglielmi | Aug 2011 | E |
8043326 | Hancock et al. | Oct 2011 | B2 |
8142456 | Rosqueta et al. | Mar 2012 | B2 |
8211160 | Garrison et al. | Jul 2012 | B2 |
8333783 | Braun et al. | Dec 2012 | B2 |
8343167 | Henson | Jan 2013 | B2 |
8361104 | Jones et al. | Jan 2013 | B2 |
8361138 | Adams | Jan 2013 | B2 |
8425541 | Masters et al. | Apr 2013 | B2 |
8444668 | Jones | May 2013 | B2 |
8470013 | Duggal et al. | Jun 2013 | B2 |
8696701 | Becking | Apr 2014 | B2 |
8715317 | Janardhan et al. | May 2014 | B1 |
8747597 | Rosqueta | Jun 2014 | B2 |
8771294 | Sepetka | Jul 2014 | B2 |
8834515 | Win et al. | Sep 2014 | B2 |
8864790 | Strauss | Oct 2014 | B2 |
8906057 | Connor et al. | Dec 2014 | B2 |
8974512 | Aboytes et al. | Mar 2015 | B2 |
8998947 | Aboytes et al. | Apr 2015 | B2 |
9211202 | Strother et al. | Dec 2015 | B2 |
9486224 | Riina et al. | Nov 2016 | B2 |
9585669 | Becking | Mar 2017 | B2 |
9687245 | Molaei | Jun 2017 | B2 |
9713475 | Divino | Jul 2017 | B2 |
9833309 | Levi et al. | Dec 2017 | B2 |
9844380 | Furey | Dec 2017 | B2 |
9844382 | Aboytes et al. | Dec 2017 | B2 |
9855051 | Aboytes et al. | Jan 2018 | B2 |
9855052 | Aboytes | Jan 2018 | B2 |
9907684 | Connor et al. | Mar 2018 | B2 |
9962146 | Hebert et al. | May 2018 | B2 |
10028745 | Morsi | Jul 2018 | B2 |
10064627 | Aboytes | Sep 2018 | B2 |
10111670 | Lorenzo | Oct 2018 | B2 |
10130372 | Griffin | Nov 2018 | B2 |
20010000797 | Mazzocchi | May 2001 | A1 |
20010001835 | Greene et al. | May 2001 | A1 |
20020062145 | Rudakov et al. | May 2002 | A1 |
20020169473 | Sepetka et al. | Nov 2002 | A1 |
20020193812 | Patel et al. | Dec 2002 | A1 |
20020193813 | Helkowski et al. | Dec 2002 | A1 |
20030004533 | Dieck et al. | Jan 2003 | A1 |
20030004568 | Ken et al. | Jan 2003 | A1 |
20030018294 | Cox | Jan 2003 | A1 |
20030028209 | Teoh et al. | Feb 2003 | A1 |
20030040772 | Hyodoh et al. | Feb 2003 | A1 |
20030055440 | Jones et al. | Mar 2003 | A1 |
20030093111 | Ken et al. | May 2003 | A1 |
20030113478 | Dang et al. | Jun 2003 | A1 |
20030114918 | Garrison et al. | Jun 2003 | A1 |
20040064093 | Hektner et al. | Apr 2004 | A1 |
20040115164 | Pierce et al. | Jun 2004 | A1 |
20040161451 | Pierce et al. | Aug 2004 | A1 |
20040172056 | Guterman et al. | Sep 2004 | A1 |
20050085836 | Raymond | Apr 2005 | A1 |
20050222580 | Gifford et al. | Oct 2005 | A1 |
20050267511 | Marks et al. | Dec 2005 | A1 |
20050277978 | Greenhalgh | Dec 2005 | A1 |
20060034883 | Dang et al. | Feb 2006 | A1 |
20060052816 | Bates et al. | Mar 2006 | A1 |
20060064151 | Guterman et al. | Mar 2006 | A1 |
20060089618 | McFerran et al. | Apr 2006 | A1 |
20060116709 | Sepetka et al. | Jun 2006 | A1 |
20060116712 | Sepetka et al. | Jun 2006 | A1 |
20060116713 | Sepetka et al. | Jun 2006 | A1 |
20060116714 | Sepetka et al. | Jun 2006 | A1 |
20060155323 | Porter et al. | Jul 2006 | A1 |
20060190025 | Lehe et al. | Aug 2006 | A1 |
20060190070 | Dieck et al. | Aug 2006 | A1 |
20060200234 | Hines | Sep 2006 | A1 |
20060206140 | Shaolian et al. | Sep 2006 | A1 |
20060206198 | Churchwell et al. | Sep 2006 | A1 |
20060206199 | Churchwell et al. | Sep 2006 | A1 |
20060241686 | Ferrera et al. | Oct 2006 | A1 |
20060247680 | Amplatz et al. | Nov 2006 | A1 |
20060271162 | Vito et al. | Nov 2006 | A1 |
20070010850 | Balgobin et al. | Jan 2007 | A1 |
20070083226 | Buiser et al. | Apr 2007 | A1 |
20070100426 | Rudakov et al. | May 2007 | A1 |
20070167876 | Euteneuer et al. | Jul 2007 | A1 |
20070167877 | Euteneuer et al. | Jul 2007 | A1 |
20070167972 | Euteneuer et al. | Jul 2007 | A1 |
20070175536 | Monetti et al. | Aug 2007 | A1 |
20070179520 | West | Aug 2007 | A1 |
20070185442 | Euteneuer et al. | Aug 2007 | A1 |
20070185443 | Euteneuer et al. | Aug 2007 | A1 |
20070185444 | Euteneuer et al. | Aug 2007 | A1 |
20070185457 | Euteneuer et al. | Aug 2007 | A1 |
20070191924 | Rudakov | Aug 2007 | A1 |
20070219619 | Dieck et al. | Sep 2007 | A1 |
20070276426 | Euteneuer | Nov 2007 | A1 |
20070276427 | Euteneuer | Nov 2007 | A1 |
20070282373 | Ashby et al. | Dec 2007 | A1 |
20070288083 | Hines | Dec 2007 | A1 |
20080082176 | Slazas | Apr 2008 | A1 |
20080097508 | Jones | Apr 2008 | A1 |
20080114391 | Dieck et al. | May 2008 | A1 |
20080114436 | Dieck et al. | May 2008 | A1 |
20080125852 | Garrison et al. | May 2008 | A1 |
20080195139 | Donald | Aug 2008 | A1 |
20080200945 | Amplatz et al. | Aug 2008 | A1 |
20080200979 | Dieck et al. | Aug 2008 | A1 |
20080221600 | Dieck et al. | Sep 2008 | A1 |
20080281350 | Sepetka et al. | Nov 2008 | A1 |
20090043375 | Rudakov et al. | Feb 2009 | A1 |
20090062841 | Amplatz et al. | Mar 2009 | A1 |
20090062899 | Dang et al. | Mar 2009 | A1 |
20090112251 | Qian et al. | Apr 2009 | A1 |
20090187214 | Amplatz et al. | Jul 2009 | A1 |
20090264978 | Dieck et al. | Oct 2009 | A1 |
20090275974 | Marchand et al. | Nov 2009 | A1 |
20090287291 | Becking et al. | Nov 2009 | A1 |
20090287292 | Becking et al. | Nov 2009 | A1 |
20090287294 | Rosqueta et al. | Nov 2009 | A1 |
20090297582 | Meyer et al. | Dec 2009 | A1 |
20090318892 | Aboytes et al. | Dec 2009 | A1 |
20090318941 | Sepetka et al. | Dec 2009 | A1 |
20090319023 | Hildebrand et al. | Dec 2009 | A1 |
20100030200 | Strauss et al. | Feb 2010 | A1 |
20100036410 | Krolik et al. | Feb 2010 | A1 |
20100139465 | Christian et al. | Jun 2010 | A1 |
20100144895 | Porter | Jun 2010 | A1 |
20100174269 | Tompkins et al. | Jul 2010 | A1 |
20100185271 | Zhang | Jul 2010 | A1 |
20100256527 | Lippert et al. | Oct 2010 | A1 |
20100256528 | Lippert et al. | Oct 2010 | A1 |
20100256601 | Lippert et al. | Oct 2010 | A1 |
20100256602 | Lippert et al. | Oct 2010 | A1 |
20100256603 | Lippert et al. | Oct 2010 | A1 |
20100256604 | Lippert et al. | Oct 2010 | A1 |
20100256605 | Lippert et al. | Oct 2010 | A1 |
20100256606 | Lippert et al. | Oct 2010 | A1 |
20100262014 | Huang | Oct 2010 | A1 |
20100268201 | Tieu et al. | Oct 2010 | A1 |
20110022149 | Cox et al. | Jan 2011 | A1 |
20110046658 | Connor et al. | Feb 2011 | A1 |
20110077620 | Debeer | Mar 2011 | A1 |
20110137332 | Sepetka et al. | Jun 2011 | A1 |
20110137405 | Wilson et al. | Jun 2011 | A1 |
20110144669 | Becking et al. | Jun 2011 | A1 |
20110152993 | Marchand et al. | Jun 2011 | A1 |
20110202085 | Loganathan et al. | Aug 2011 | A1 |
20110208227 | Becking | Aug 2011 | A1 |
20110224776 | Sepetka et al. | Sep 2011 | A1 |
20110265943 | Rosqueta et al. | Nov 2011 | A1 |
20110319926 | Becking et al. | Dec 2011 | A1 |
20120022572 | Braun et al. | Jan 2012 | A1 |
20120041472 | Tan et al. | Feb 2012 | A1 |
20120101510 | Lenker et al. | Apr 2012 | A1 |
20120116350 | Strauss et al. | May 2012 | A1 |
20120165919 | Cox et al. | Jun 2012 | A1 |
20120197283 | Marchand et al. | Aug 2012 | A1 |
20120239074 | Aboytes et al. | Sep 2012 | A1 |
20120283769 | Cruise et al. | Nov 2012 | A1 |
20120316598 | Becking et al. | Dec 2012 | A1 |
20120316632 | Gao | Dec 2012 | A1 |
20120330341 | Becking et al. | Dec 2012 | A1 |
20120330347 | Becking et al. | Dec 2012 | A1 |
20120330348 | Strauss et al. | Dec 2012 | A1 |
20130066357 | Aboytes et al. | Mar 2013 | A1 |
20130066360 | Becking et al. | Mar 2013 | A1 |
20130085522 | Becking et al. | Apr 2013 | A1 |
20130116722 | Aboytes et al. | May 2013 | A1 |
20130253572 | Molaei et al. | Sep 2013 | A1 |
20130274866 | Cox et al. | Oct 2013 | A1 |
20140012307 | Franano et al. | Jan 2014 | A1 |
20140058420 | Hannes et al. | Feb 2014 | A1 |
20140316012 | Freyman et al. | Oct 2014 | A1 |
20140371734 | Truckai | Dec 2014 | A1 |
20150182227 | Le et al. | Jul 2015 | A1 |
20150209050 | Aboytes | Jul 2015 | A1 |
20150216684 | Enzmann et al. | Aug 2015 | A1 |
20150250628 | Monstadt et al. | Sep 2015 | A1 |
20150272590 | Aboytes et al. | Oct 2015 | A1 |
20150297240 | Divino et al. | Oct 2015 | A1 |
20150313737 | Tippett et al. | Nov 2015 | A1 |
20150327843 | Garrison | Nov 2015 | A1 |
20150342613 | Aboytes et al. | Dec 2015 | A1 |
20160022445 | Ruvalcaba et al. | Jan 2016 | A1 |
20160066921 | Seifert et al. | Mar 2016 | A1 |
20160135984 | Rudakov et al. | May 2016 | A1 |
20160206320 | Connor | Jul 2016 | A1 |
20160206321 | Connor | Jul 2016 | A1 |
20160262766 | Aboytes et al. | Sep 2016 | A1 |
20160317158 | Lorenzo | Nov 2016 | A1 |
20170150971 | Hines | Jun 2017 | A1 |
20170156903 | Shobayashi | Jun 2017 | A1 |
20170189035 | Porter | Jul 2017 | A1 |
20170224350 | Shimizu et al. | Aug 2017 | A1 |
20170266023 | Thomas | Sep 2017 | A1 |
20170281194 | Divino | Oct 2017 | A1 |
20170340333 | Badruddin et al. | Nov 2017 | A1 |
20170367708 | Mayer et al. | Dec 2017 | A1 |
20180036012 | Aboytes et al. | Feb 2018 | A1 |
20180049859 | Stoppenhagen et al. | Feb 2018 | A1 |
20180125501 | Aboytes | May 2018 | A1 |
20180125686 | Lu | May 2018 | A1 |
20180132859 | Aboytes | May 2018 | A1 |
20180132862 | Aboytes | May 2018 | A1 |
20180140305 | Connor | May 2018 | A1 |
20180161185 | Kresslein et al. | Jun 2018 | A1 |
20180193025 | Walzman | Jul 2018 | A1 |
20180193026 | Yang et al. | Jul 2018 | A1 |
20180206852 | Moeller | Jul 2018 | A1 |
20190053811 | Garza et al. | Feb 2019 | A1 |
20190059907 | Rosqueta | Feb 2019 | A1 |
20200138447 | Rosqueta | May 2020 | A1 |
Number | Date | Country |
---|---|---|
2812012 | Mar 2012 | CA |
102011102933 | Dec 2012 | DE |
0717969 | Jun 1996 | EP |
1295563 | Mar 2003 | EP |
1813213 | Aug 2007 | EP |
2208483 | Jul 2010 | EP |
2609888 | Jul 2013 | EP |
2890306 | Jul 2015 | EP |
2890306 | Mar 2007 | FR |
2005261951 | Sep 2005 | JP |
2008521492 | Jun 2008 | JP |
2010523260 | Jul 2010 | JP |
9406502 | Mar 1994 | WO |
9409705 | May 1994 | WO |
9907294 | Feb 1999 | WO |
9929260 | Jun 1999 | WO |
0164112 | Sep 2001 | WO |
02054980 | Jul 2002 | WO |
02089863 | Nov 2002 | WO |
2005099634 | Oct 2005 | WO |
2006034149 | Mar 2006 | WO |
2007121405 | Oct 2007 | WO |
2008036156 | Mar 2008 | WO |
2008074027 | Jun 2008 | WO |
2009014528 | Jan 2009 | WO |
2010009019 | Jan 2010 | WO |
2010027363 | Mar 2010 | WO |
2010077599 | Jul 2010 | WO |
2011066962 | Jun 2011 | WO |
2011095966 | Aug 2011 | WO |
2012034135 | Mar 2012 | WO |
2013112944 | Aug 2013 | WO |
2013138615 | Sep 2013 | WO |
2014105932 | Jul 2014 | WO |
2013138615 | Sep 2014 | WO |
2017074411 | May 2017 | WO |
2018051187 | Mar 2018 | WO |
Entry |
---|
European Search Report dated Feb. 5, 2021; European Patent Application No. 18849224.3; 10 pages. |
Number | Date | Country | |
---|---|---|---|
20200138447 A1 | May 2020 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15683627 | Aug 2017 | US |
Child | 16738968 | US |